Tarsus Pharmaceuticals EBITDA vs. Profit Margin
| TARS Stock | USD 50.42 2.03 3.87% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -131.7 M | Current Value -125.1 M | Quarterly Volatility 44.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.05 | 0.9087 |
|
|
For Tarsus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tarsus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tarsus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tarsus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tarsus Pharmaceuticals over time as well as its relative position and ranking within its peers.
Tarsus |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tarsus Pharmaceuticals. If investors know Tarsus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tarsus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.75) | Revenue Per Share 3.571 | Quarterly Revenue Growth 24.718 | Return On Assets (0.27) | Return On Equity (0.60) |
The market value of Tarsus Pharmaceuticals is measured differently than its book value, which is the value of Tarsus that is recorded on the company's balance sheet. Investors also form their own opinion of Tarsus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tarsus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tarsus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tarsus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tarsus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tarsus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tarsus Pharmaceuticals Profit Margin vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Tarsus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Tarsus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Tarsus Pharmaceuticals is rated below average in ebitda category among its peers. It is rated fifth in profit margin category among its peers . At this time, Tarsus Pharmaceuticals' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tarsus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tarsus Profit Margin vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Tarsus Pharmaceuticals |
| = | (131.67 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Tarsus Pharmaceuticals |
| = | (1.04) % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Tarsus Profit Margin Comparison
Tarsus Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Tarsus Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Tarsus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tarsus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Tarsus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Tarsus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2 K | -2.1 K | |
| Net Interest Income | 6.4 M | 6.8 M | |
| Operating Income | -143.2 M | -136 M | |
| Net Loss | -107.6 M | -102.2 M | |
| Income Before Tax | -135.9 M | -129.1 M | |
| Total Other Income Expense Net | 7.3 M | 7.6 M | |
| Net Loss | -55.9 M | -53.1 M | |
| Net Loss | -135.9 M | -129.1 M | |
| Income Tax Expense | 709.1 K | 744.6 K | |
| Interest Income | 9.5 M | 10 M | |
| Non Operating Income Net Other | -785.5 K | -824.7 K | |
| Change To Netincome | 16.1 M | 16.9 M | |
| Net Loss | (4.62) | (4.39) | |
| Income Quality | 0.86 | 0.70 | |
| Net Income Per E B T | 0.90 | 0.80 |
Tarsus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Tarsus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tarsus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tarsus Pharmaceuticals' important profitability drivers and their relationship over time.
Use Tarsus Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tarsus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tarsus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Tarsus Pharmaceuticals Pair Trading
Tarsus Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Tarsus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tarsus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tarsus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tarsus Pharmaceuticals to buy it.
The correlation of Tarsus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tarsus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tarsus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tarsus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Tarsus Pharmaceuticals position
In addition to having Tarsus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Growth Thematic Idea Now
Tech Growth
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 66 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.